Lumito AB publishes interim report for the third quarter of 2025

Financial overviewThird quarter 2025, 1 July – 30 September• Net sales amounted to 0 (0) KSEK, capitalised development contributed with 0 (418) KSEK• The net loss amounted to -9 511 (-10 844) KSEK.• Basic and diluted earnings per share amounted to -0.04 (-0.05) SEK.• Cash flow during the third quarter amounted to -3 084 (-6 156) […]

Invitation to webinar in connection with Lumito AB’s Q3 2025 Interim Report

Lumito AB (publ) (“Lumito” or the “Company”) will publish its report for the third quarter of 2025 on 27 November 2025. In connection with the publication, shareholders, investors, and other stakeholders are invited to a webinar on the same day at 14:00 CET. During the session, the Company’s CEO, Sanna Wallenborg, will provide a brief introduction […]

Lumito AB and Katana Labs GmbH sign Letter of Intent and enter into a strategic partnership to enhance biomarker detection and quantification

Lumito AB (publ) ("Lumito" or the "Company") today announces that the Company and Katana Labs GmbH (“Katana Labs”) have signed a Letter of Intent (“LOI) formalising a strategic partnership to jointly commercialise an end-to-end, ultra-sensitive immunohistochemistry (IHC) workflow that integrates Lumito’s labelling and scanning technology with Katana Labs’ AI-powered image analysis platform. This is a […]

Lumito AB announces terms of rights issue of units of approximately SEK 60 million

THE INFORMATION IN THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED KINGDOM, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE THE RELEASE, PUBLICATION OR DISTRIBUTION OF THE INFORMATION WOULD BE CONTRARY TO OR REQUIRE […]

Lumito AB publishes Quarterly Report 2, 2025

Financial overview Second quarter 2025, 1 April to 30 June • Net sales amounted to KSEK 0 (0). • Result after taxes amounted to KSEK -11 275 (-8 132) TSEK. • Basic and diluted earnings per share amounted to SEK -0,04 (-0,04). • Cash flow from operating activities after change in working capital amounted to […]

Lumito AB publishes Quarterly Report 1, 2025

First quarter 2025, January 1 to March 31 • Net sales amounted to TSEK 0 (17).• Result after taxes amounted to TSEK -11 803 (-7 113).• Earnings per share before and after dilution amounted to SEK -0,04 (-0,03).• Cash flow from operating activities after changes in working capital amounted to TSEK -6 784 (-7,178).• Cash […]

Lumito AB publishes Quarterly Report 3, 2024

Financial overview of the third quarter July 1 to September 30, 2024 Net sales amounted to TSEK 0 (0). Result after taxes amounted to TSEK -10 843 (-5 358). Earnings per share before and after dilution amounted to SEK -0,05 (-0,03). Cash flow from operating activities after changes in working capital amounted to TSEK -5 567 […]

Lumito AB publishes Quarterly Report 2, 2024

First half of the year1 January – 30 June 2024 Net sales amounted to KSEK 17 (0). Result after taxes amounted to KSEK -15,244 (-14,668). Basic and diluted earnings per share amounted to SEK -0,06 (-0,07). Cash flow from operating activities after change in working capital amounted to KSEK -16,247 (-13,734). Cash and cash equivalents […]

Lumito AB publishes Quarterly Report 1, 2024

Financial overview of the first quarter January 1 to March 31, 2024 Net sales amounted to TSEK 0 (0). Result after taxes amounted to TSEK -7 113 (-7 245). Earnings per share before and after dilution amounted to SEK -0,03 (-0,04). Cash flow from operating activities after changes in working capital amounted to TSEK -7 180 […]

Lumito AB publishes Quarterly Report 4, 2023

Financial overviewFourth quarterOctober 1 – December 31, 2023 Net sales amounted to TSEK 0 (0). Result after taxes amounted to TSEK -5 777 (-6 612). Earnings per share before and after dilution amounted to SEK -0,03 (-0,03). Cash flow from operating activities after changes in working capital amounted to TSEK -5 480 (-5 153). Full […]